focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Kinda feel the same way, fwiw. Surely the mcap will be in the hundreds of millions at some point but how many shares will be in issue by then, will us shareholders benefit? Holding this share has been a nasty learning curve, given it has done everything that has been required science wise. Reminding myself of BoA and Invesco investment. Partner news in q3 feels pivotal.
31p. Bearable
Doesn't give a price.
Grrr
He seemed way more keen to deal directly with Bots Power Corp than go through another arduous tender process with a new govt. The tender process got out of hand and doing the former would allow them to go down the 1MW to 10MW route which is what he always wanted.
From 29s to 32s. Barking mad stock.
Indeed. Real money made over 5 years rather than 5 minutes and so on. Difficult to ignore the daily fluctuations sometimes. Atb.
Agreed from a scientific viewpoint the milestones ticked off are outstanding. But investors judge a company's success by the SP, nothing else. It is like saying a football club is a roaring success when it has been relegated just because it does great work in the community. I also wouldn't put the Nasdaq listing down as a triumph or achievement thus far, however difficult it was to accomplish. With just 7 staff they really dont seem to be getting the message out In the US, no matter how many presentations they give. That said, sub £80m mcap now seems a joke/gift horse for a drug that has passed p3 (a brilliant achievement) and is less than a year away from probable approval and helping a lot of people. Hopefully q2 submission and possible q3 partnership will the sp a shot in the arm.
There was only 3 trades on Nasdaq yesterday. I really don't understand the lack of interest over there, given all the hassle it took to list.
Vox podcast today. GL says most sections complete and just waiting on 'additional info from outside providers'. As said, they only get one shot at this so best get it right
Nda q2. No problem with them spending a bit of extra time to get it done perfectly.
Company tweet with this link https://www.ogauthority.co.uk/news-publications/news/2018/extra-28-billion-barrels-identified-in-oga-s-projections-to-2050/
This link is about tetraphase failing earlier this month and not iclaprim, but has the line at the end about antibiotics being 'not so easy to market when they do pass muster'. Why is that, given the obvious need and growing resistance? https://endpts.com/tetraphases-second-phiii-for-its-lead-antibiotic-fails-in-a-repeat-setback-for-utis/